Vascular Solutions 10-Q 22 Oct 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 18, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	VASCULAR SOLUTIONS INC
Entity Central Index Key	1030206
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		16,832,783
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Sep-13

Consolidated_Balance_Sheets_un

Consolidated Balance Sheets (unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$24,102,000	$11,554,000
Accounts receivable, net of reserves of $200,000 and $185,000 in 2013 and 2012, respectively	14,460,000	13,780,000
Inventories	14,260,000	13,737,000
Prepaid expenses and other	2,806,000	2,670,000
Current portion of deferred tax assets	6,800,000	6,800,000
Total current assets	62,428,000	48,541,000
Property, plant and equipment, net	16,173,000	14,756,000
Goodwill	10,431,000	10,387,000
Intangible assets, net	12,089,000	12,325,000
Deferred tax assets, net of current portion and liabilities	1,049,000	1,993,000
Total assets	102,170,000	88,002,000
Current liabilities:
Accounts payable	3,975,000	3,842,000
Accrued compensation	4,283,000	4,123,000
Accrued expenses	2,720,000	1,927,000
Accrued royalties	237,000	288,000
Current portion of deferred revenue and contingent consideration	520,000	345,000
Total current liabilities	11,735,000	10,525,000
Long-term deferred revenue and contingent consideration, net of current portion	457,000	610,000
Shareholders' equity:
Common stock, $0.01 par value: Authorized shares - 40,000,000 Issued and outstanding shares - 16,832,783 - 2013;16,378,923 - 2012	168,000	164,000
Additional paid-in capital	89,601,000	84,160,000
Accumulated other comprehensive earnings	-89,000	-150,000
Retained earnings (accumulated deficit)	298,000	-7,307,000
Total shareholders' equity	89,978,000	76,867,000
Total liabilities and shareholders' equity	$102,170,000	$88,002,000

Consolidated_Balance_Sheets_un1

Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Reserves for accounts receivable	$200,000	$185,000
Shareholders' equity:
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, authorized shares (in shares)	40,000,000	40,000,000
Common stock, shares issued (in shares)	16,832,783	16,378,923
Common stock, shares outstanding (in shares)	16,832,783	16,378,923

Consolidated_Statements_of_Ear

Consolidated Statements of Earnings (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net revenue:
Product revenue	$27,926,000	$24,465,000	$81,197,000	$72,821,000
License and collaboration revenue	83,000	87,000	230,000	262,000
Total revenue	28,009,000	24,552,000	81,427,000	73,083,000
Product costs and operating expenses:
Cost of goods sold	9,197,000	8,183,000	26,432,000	24,252,000
Collaboration expenses	32,000	0	41,000	0
Research and development	3,140,000	2,936,000	10,027,000	8,964,000
Clinical and regulatory	997,000	1,022,000	3,259,000	3,326,000
Sales and marketing	6,706,000	6,188,000	20,462,000	19,279,000
General and administrative	2,362,000	1,714,000	6,871,000	5,013,000
Litigation	812,000	0	812,000	0
Medical device excise taxes	339,000	0	995,000	0
Amortization of purchased technology and intangibles	404,000	359,000	1,162,000	1,032,000
Total product costs and operating expenses	23,989,000	20,402,000	70,061,000	61,866,000
Operating earnings	4,020,000	4,150,000	11,366,000	11,217,000
Other earnings (expenses):
Interest expense	-3,000	-3,000	-9,000	-10,000
Foreign exchange gain (loss)	7,000	9,000	-2,000	-11,000
Earnings before income taxes	4,024,000	4,156,000	11,355,000	11,196,000
Income tax expense	-1,352,000	-1,591,000	-3,750,000	-4,338,000
Net earnings	$2,672,000	$2,565,000	$7,605,000	$6,858,000
Net earnings per share - basic (in dollars per share)	$0.16	$0.16	$0.47	$0.43
Net earnings per share - diluted (in dollars per share)	$0.16	$0.16	$0.45	$0.42

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Earnings (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements of Comprehensive Earnings (unaudited) [Abstract]
Net earnings	$2,672,000	$2,565,000	$7,605,000	$6,858,000
Other comprehensive earnings (loss), net of $0 tax: Foreign currency translation adjustments	192,000	128,000	61,000	-53,000
Comprehensive earnings	$2,864,000	$2,693,000	$7,666,000	$6,805,000

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Earnings (unaudited) (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements of Comprehensive Earnings (unaudited) [Abstract]
Other comprehensive earnings (loss), Foreign currency translation adjustments, tax	$0	$0	$0	$0

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities
Net earnings	$7,605,000	$6,858,000
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	2,109,000	1,578,000
Amortization	1,162,000	1,032,000
Stock-based compensation	2,567,000	2,221,000
Deferred taxes, net	2,275,000	3,634,000
Excess tax benefit from stock-based compensation	-1,331,000	0
Change in fair value of contingent consideration	-79,000	-96,000
Gain on the sale of property and equipment	-22,000	-1,000
Change in accounts receivable allowance	15,000	5,000
Changes in operating assets and liabilities:
Accounts receivable	-691,000	-2,168,000
Inventories	-685,000	1,062,000
Prepaid expenses and other	-176,000	-282,000
Accounts payable	127,000	621,000
Accrued expenses and compensation	659,000	-205,000
Amortization of deferred license fees and other deferred revenue	101,000	-259,000
Net cash provided by operating activities	13,636,000	14,000,000
Investing activities
Purchase of property and equipment	-3,486,000	-2,370,000
Cash paid for acquisitions and license	-500,000	-7,000,000
Proceeds from the sale of property and equipment	22,000	10,000
Net cash used in investing activities	-3,964,000	-9,360,000
Financing activities
Repurchase of common shares	-1,211,000	-5,413,000
Excess tax benefit from stock-based compensation	1,331,000	0
Proceeds from the exercise of stock options and sale of stock, net of expenses	2,759,000	954,000
Net cash provided by (used in) financing activities	2,879,000	-4,459,000
Increase (decrease) in cash and cash equivalents	12,551,000	181,000
Effect of exchange rate changes on cash and cash equivalents	-3,000	6,000
Cash and cash equivalents at beginning of period	11,554,000	13,726,000
Cash and cash equivalents at end of period	24,102,000	13,913,000
Supplemental disclosure of cash flow
Cash paid for interest	9,000	10,000
Cash paid for taxes	$1,499,000	$751,000

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Basis of Presentation [Abstract]
Basis of Presentation	-1	Basis of Presentation
	The accompanying unaudited consolidated financial statements of Vascular Solutions, Inc. (the Company) have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all normal, recurring adjustments considered necessary for a fair presentation have been included.  The consolidated financial statements should be read in conjunction with the audited consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission.  Interim results of operations are not necessarily indicative of the results to be expected for the full year or any other interim periods.

Net_Earnings_per_Share

Net Earnings per Share	9 Months Ended
	Sep. 30, 2013
Net Earnings per Share [Abstract]
Net Earnings per Share	-2	Net Earnings per Share
	In accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share, basic net earnings per share for the three and nine months ended September 30, 2013 and 2012 is computed by dividing net earnings by the weighted average common shares outstanding during the periods presented.  Diluted net earnings per weighted average common share is computed by dividing net earnings by the weighted average common shares outstanding during the period, increased to include dilutive potential common shares issuable upon the exercise of stock options and restricted stock awards that were outstanding during the period.
	Weighted average common shares outstanding for the three and nine months ended September 30, 2013 and 2012 were as follows:
			Three Months Ended				Nine Months Ended
			September 30,				September 30,
			2013		2012		2013		2012
			(unaudited)				(unaudited)
	Weighted average shares outstanding – basic			16,451,000		15,885,000		16,299,000		15,960,000
	Weighted average shares outstanding – diluted			17,067,000		16,389,000		16,894,000		16,341,000

Revenue_Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2013
Revenue Recognition [Abstract]
Revenue Recognition	(3)	Revenue Recognition
	In the United States, the Company sells its products and services directly to hospitals and clinics.  Revenue is recognized in accordance with generally accepted accounting principles as outlined in ASC 605-10-S99, Revenue Recognition, which requires that four basic criteria be met before revenue can be recognized: (i) persuasive evidence of an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered.  The Company recognizes revenue as products are shipped and title passes to customers based on FOB shipping point terms.  The Company negotiates credit terms on a customer-by-customer basis and products are shipped at an agreed-upon price.  All product returns must be pre-approved and, if approved, customers are subject to a 20% restocking charge.
	In all international markets, the Company sells its products to international distributors which subsequently resell the products to hospitals and clinics.  The Company has agreements with each of its distributors which provide that title and risk of loss pass to the distributor upon shipment of the products to the distributor.  The Company warrants that its products are free from manufacturing defects at the time of shipment to the distributor.  Revenue is recognized upon shipment of products to distributors following the receipt and acceptance of a distributor’s purchase order.  Allowances are provided for estimated returns and warranty costs at the time of shipment.
	The Company also generates revenues from license agreements and recognizes the revenue when earned.  In accordance with ASC 605, for revenues which contain multiple deliverables, the Company separates the deliverables into separate accounting units if they meet the following criteria: (i) the delivered items have a stand-alone value to the customer; (ii) the fair value of any undelivered items can be reliably determined; and (iii) if the arrangement includes a general right of return, delivery of the undelivered items is probable and substantially controlled by the seller.  Deliverables that do not meet these criteria are combined with one or more other deliverables into one accounting unit.  Revenue from each accounting unit is recognized based on the applicable accounting literature, primarily ASC 605.
	Starting in January 2012, the Company began to generate revenue from selling a reprocessing service for ClosureFast® radiofrequency catheters.  In accordance with ASC 605-45, the Company recognizes this revenue gross, with the amount paid to the supplier of the reprocessing service reflected as cost of sales.
	In accordance with ASC 605-45-45, the Company includes shipping and handling revenues in net revenue, and shipping and handling costs in cost of sales.
	The Patient Protection and Affordable Care Act and Health Care and Education Affordability Reconciliation Act were enacted into law in the U.S. in 2010.  The legislation imposed a 2.3 percent excise tax on medical device manufacturers on the U.S. sales of Class I, II and III medical devices beginning January 1, 2013.  The Company has recorded this tax expense as a separate line in the Consolidated Statement of Operations.  The Company has not invoiced its customers for this tax as a separate charge and the tax is not included as an element of revenue.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventories [Abstract]
Inventories	-4	Inventories
	Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market.  Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value.  Inventories are comprised of the following:
			September 30,		31-Dec-12
			2013
			(unaudited)
	Raw materials		$	6,292,000	$	6,674,000
	Work-in-process			1,137,000		780,000
	Finished goods			6,831,000		6,283,000
			$	14,260,000	$	13,737,000

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Other Intangible Assets	-5	Goodwill and Other Intangible Assets
	The changes in the carrying amount of goodwill and acquired intangible assets for the nine months ended September 30, 2013 are as follows:
					Acquired
			Goodwill		Intangibles
			(unaudited)
	Balance at December 31, 2012		$	10,387,000	$	12,325,000
	Amortization			–		(1,162,000	)
	Purchased license			–		900,000
	Foreign currency translation adjustments			44,000		26,000
	Balance at September 30, 2013		$	10,431,000	$	12,089,000

Credit_Risk_and_Allowance_for_

Credit Risk and Allowance for Doubtful Accounts	9 Months Ended
	Sep. 30, 2013
Credit Risk and Allowance for Doubtful Accounts [Abstract]
Credit Risk and Allowance for Doubtful Accounts	-6	Credit Risk and Allowance for Doubtful Accounts
	The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  This allowance is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay.  The Company does not accrue interest on past due accounts receivable.  Receivables are written off only after all collection attempts have failed and are based on individual credit evaluation and the specific circumstances of the customer.  At September 30, 2013 and December 31, 2012, the allowance for doubtful accounts was $150,000 and $130,000, respectively.
	All product returns must be pre-approved, and if approved, customers are subject to a 20% restocking charge.  The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns, which is included with the allowance for doubtful accounts on our balance sheet.  At September 30, 2013 and December 31, 2012, the sales and return allowance was $50,000 and $55,000, respectively.
	Accounts receivable are shown net of the combined total of the allowance for doubtful accounts and allowance for sales returns of $200,000 and $185,000 at September 30, 2013 and December 31, 2012, respectively.

Concentrations_of_Credit_and_O

Concentrations of Credit and Other Risks	9 Months Ended
	Sep. 30, 2013
Concentrations of Credit and Other Risks [Abstract]
Concentrations of Credit and Other Risks	-7	Concentrations of Credit and Other Risks
	In the United States, the Company sells its products and services directly to hospitals and clinics.  In all international markets, the Company sells its products to distributors who, in turn, sell to hospitals and clinics.
	With respect to accounts receivable, the Company performs credit evaluations of its customers and does not require collateral.  No single customer represented greater than 10% of gross accounts receivable as of either September 30, 2013 or December 31, 2012.  There have been no material losses on customer receivables.
	Revenue by geographic destination as a percentage of total net revenue for the three and nine month periods ended September 30, 2013 and 2012 was 85% and 84% in the United States and 15% and 16% in international markets, respectively.  No single customer represented greater than 10% of the total net revenue for the three and nine months ended September 30, 2013 and 2012.

Dependence_on_Key_Suppliers

Dependence on Key Suppliers	9 Months Ended
	Sep. 30, 2013
Dependence on Key Suppliers [Abstract]
Dependence on Key Suppliers	-8	Dependence on Key Suppliers
	The Company purchases certain key components from single-source suppliers.  Any significant component delay or interruption could require the Company to qualify new sources of supply, if available, and could have a material adverse effect on the Company’s financial condition and results of operations.
	King Pharmaceuticals
	The Company purchases its requirements for thrombin (a component in the Hemostat products) under a Thrombin-JMI® Supply Agreement entered into with King Pharmaceuticals, Inc. (“King”) on January 9, 2007.  King was acquired by Pfizer, Inc. on February 28, 2011.  Under the terms of the Thrombin-JMI Supply Agreement, King agrees to manufacture and supply thrombin to the Company on a non-exclusive basis.  The Thrombin-JMI Supply Agreement does not contain any minimum purchase requirements.  King agrees to supply the Company with such quantity of thrombin as the Company may order at a fixed price throughout the term of the Thrombin-JMI Supply Agreement as adjusted for inflation, variations in potency and other factors.  The Thrombin-JMI Supply Agreement has an initial term of 10 years, followed by successive automatic one-year extensions, subject to termination by the parties under certain circumstances, including: (i) termination by King without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to the Company, and (ii) termination by the Company without cause any time after the fifth anniversary of the date of the Thrombin-JMI Supply Agreement upon five years prior written notice to King provided that the Device Supply Agreement, which the Company also entered into with King on January 9, 2007, has expired on its terms or the parties have agreed to terminate it.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]
Commitments and Contingencies	-9	Commitments and Contingencies
	Boston Scientific Corporate Litigation
	On May 16, 2013, the Company filed a patent infringement complaint in the United States District Court for the District of Minnesota against Boston Scientific Corporation (Boston Scientific).  The complaint alleges that Boston Scientific has infringed three patents owned by the Company concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla™ guide extension catheter, which received FDA 510(k) clearance in March 2013.  The Company is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter, as well as damages for lost profits and legal costs.  On June 10, 2013, the Company filed a motion for preliminary injunction asking the court to enjoin Boston Scientific’s manufacture and sale of the Guidezilla catheter during the pendency of the litigation.  On July 11, 2013, Boston Scientific filed its answer and counterclaim, alleging that the Company’s patents are invalid, that the Guidezilla catheter does not infringe, and that the Company’s manufacture and sale of its GuideLiner® catheter violates a U.S. patent owned by Boston Scientific that has recently expired.  The counterclaim seeks unspecified damages and payment of Boston Scientific’s attorney’s fees, expenses and costs.  The Court held a hearing on the Company’s motion for a preliminary injunction on August 27, 2013, but has not yet issued its ruling.
	Terumo Medical Corporation Litigation
	On February 14, 2013, Terumo Corporation and Terumo Medical Corporation (Terumo) filed a complaint for patent and trademark infringement against the Company and Lepu Medical Technology (Beijing) Co. in the United States District Court for the District of New Jersey.  The complaint alleged that the R-Band™ radial compression device that was previously distributed by the Company and manufactured by Lepu Medical Technology infringed a Terumo patent, U.S. Patent No. 7,498,477 (the ‘477 Patent). Terumo also alleged that the Company’s previous use of the product name R-Band infringed trademark rights it claims in its product name TR-Band™.  Terumo’s complaint sought unspecified damages and an injunction against further sales of the R-Band product.  In May 2013, the Company introduced its Vasc™ Band radial compression hemostatic device.  On July 29, 2013, Terumo filed an amended complaint, alleging that the Company’s Vasc™ Band product also infringed the ‘477 Patent.  On October 11, 2013, the Company and Terumo reached an agreement to settle the litigation, whereby the Company will make a one-time payment to Terumo in the amount of $812,000 and Terumo will agree that the current design of the Vasc Band product does not infringe any claim of any issued Terumo patent and will not sue the Company on any future issued patent concerning the current design of the Vasc Band. The Company’s settlement payment was accrued as litigation expense in the third quarter of 2013 and is expected to be paid to Terumo in the fourth quarter of 2013.
	Governmental Proceedings
	On June 28, 2011, the Company received a subpoena from the U.S. Attorney’s Office for the Western District of Texas under the Health Insurance Portability & Accountability Act of 1996 (HIPAA) requesting the production of documents related to the Company’s Vari-Lase products, and in particular the use of the Vari-Lase® Short Kit for the treatment of perforator veins.  The U.S. Attorney’s Office also has commenced a criminal investigation of the same matter.  The Vari-Lase Short Kit has been sold under a 510(k) clearance for the treatment of incompetence and reflux of superficial veins in the lower extremity since 2007 with total U.S. sales through September 30, 2013 of approximately $471,000 (0.1% of the Company’s total U.S. sales for such period) and has not been the subject of any reported serious adverse clinical event.  On August 14, 2012, the United States District Court for the Western District of Texas unsealed a qui tam complaint that had been filed on November 19, 2010 by Desalle Bui, a former sales employee of the Company, which is the basis for the U.S. Attorney’s civil investigation, to which the federal government, after three extensions of time, has elected to intervene.  The complaint contains allegations of off-label promotion of Vari-Lase products for the treatment of perforator veins, re-use of single-use Vari-Lase products and Company-provided kickbacks to physicians, resulting in alleged damages to the government of approximately $20 million.  An amended complaint limited to allegations of off-label promotion of the Vari-Lase Short Kit resulting in an unspecified amount of damages and penalties was filed by the U.S. Attorney’s Office in December 2012.  The parties are in the discovery phase of the civil case, and the Court has set the civil case for trial in January 2015.  No schedule has been established for the criminal investigation.
	The Company believes the allegations are factually inaccurate and without merit, and therefore the Company intends to both fully comply with the U.S. Attorney’s investigations and defend the litigation.
	From time to time, the Company is involved in additional legal proceedings arising in the normal course of business.  As of the date of this report, the Company is not a party to any legal proceeding not described in this section in which an adverse outcome would reasonably be expected to have a material adverse effect on the Company’s results of operations or financial condition.
	King Agreements
	On January 9, 2007, the Company entered into a License Agreement and a Device Supply Agreement with King (See Note 8).  King was acquired by Pfizer, Inc. on February 28, 2011.  Under the License Agreement, the Company licensed the exclusive rights to the Company’s products Thrombi-Pad®, Thrombi-Gel® and Thrombi-Paste® to King in exchange for a one-time license fee.  Under the Device Supply Agreement, the Company agreed to manufacture the licensed products for sale to King in exchange for an initial payment.  The unamortized license fee was $662,000 and $815,000 at September 30, 2013 and December 31, 2012, respectively.  Amortization of the deferred revenue will be $51,000 per quarter for the remainder of the 10-year license period.  The amortization of license fee was $153,000 for the nine months ended September 30, 2013 and 2012.
	Nicolai GmbH Agreement
	Effective April 1, 2008 the Company entered into a five-year distribution agreement with Nicolai GmbH.  As a result of entering into this distribution agreement, the Company no longer maintains a direct sales force in Germany.  In connection with this distribution agreement, the Company received 500,000 Euros from Nicolai GmbH, which was deferred and was being recognized ratably over the five-year term of the distribution agreement.
	The agreement included provisions requiring the Company to pay Nicolai GmbH specific amounts if the Company terminated the distribution agreement prior to the end of the five-year term.  The Company did not terminate the distribution agreement prior to the termination date.  The unamortized license fee was $-0- and $36,000 at September 30, 2013 and December 31, 2012, respectively.  The amortization of license fee was $36,000 and $73,000 for the nine months ended September 30, 2013 and 2012, respectively.
	Radius Medical Technologies, Inc. Contingent Consideration
	On October 20, 2010, the Company acquired the assets related to the snare and retrieval product line business from Radius Medical Technologies, Inc. and Radius Medical, LLC (collectively, “Radius”).  Under the terms of the agreement the Company paid Radius a total of $6,449,000, consisting of $5,000,000 paid in cash at October 20, 2010 and $1,449,000 which was paid on June 9, 2011 upon the successful completion of the transfer of the manufacturing processes from Radius to the Company along with all fixed assets and inventory.  In addition, Radius is entitled to receive an annual cash contingent consideration payment based on 25% of the net sales of the acquired products which exceed $2.0 million, $2.5 million, and $3.0 million for the calendar years ending December 31, 2011, 2012 and 2013, respectively.  The range of possible contingent consideration payments is from $-0- if no sales are made in excess of the thresholds, to an undeterminable amount as the agreement does not contain a cap on the payment amounts.  In accordance with ASC 805, Business Combinations, a reduction of $79,000, $136,000, $96,000 and $586,000 in the liability amount for contingent consideration was recorded at May 31, 2013, December 31, 2012, March 31, 2012 and September 30, 2011, respectively, and a corresponding gain was recognized in operating expenses within the general and administrative expenses.  At September 30, 2013 and December 31, 2012, the Company has recorded a liability for these contingent consideration payments in the amount of $-0- and $79,000, respectively.

Lines_of_Credit

Lines of Credit	9 Months Ended
	Sep. 30, 2013
Lines of Credit [Abstract]
Lines of Credit	-10	Lines of Credit
	On December 6, 2012, the Company modified and extended its secured asset-based revolving credit agreement with U.S. Bank National Association dated December 21, 2009 (as amended on December 20, 2011 and December 20, 2010).  The revolving credit agreement is a one-year, $10,000,000 facility with availability based primarily on eligible customer receivables, inventory and property and equipment.  The revolving credit agreement bears interest equal to the one-month LIBOR rate plus 1.60% and is secured by a first security interest on all of the Company’s assets.  The revolving credit agreement requires a quarterly payment based on an annual fee of 0.125% of the average unused portion of the committed revolving line as determined by the bank and reviewed by management.
	The revolving credit agreement includes one covenant that the Company cannot have a maximum cash flow leverage ratio greater than 2.5 to 1.  The calculation of this covenant is determined by multiplying annual lease expense times six and adding any loans, then dividing this amount by the sum of earnings before interest, taxes, depreciation, amortization and annual operating lease payments.  The covenant is computed quarterly based on a rolling 12-month period.  The Company was in compliance with the covenant as of September 30, 2013.
	As of and through-out the nine months ended September 30, 2013, the Company had no outstanding balance against the revolving credit agreement.  Based on the Company’s eligible customer receivables, inventory, property and equipment and cash balances, $10,000,000 was available for borrowing as of September 30, 2013.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Taxes [Abstract]
Income Taxes	-11	Income Taxes
	The Company is subject to income tax in numerous jurisdictions and at various rates and the use of estimates is required in determining the provision for income taxes.  For the nine month periods ended September 30, 2013 and 2012, the Company recorded a provision for taxes of $3,750,000 and $4,338,000 on earnings before tax of $11,355,000 and $11,196,000 resulting in an effective income tax rate of 33% and 39%, respectively.  The reduced effective tax rate of 33% for the nine months ended September 30, 2013 was due mainly to the impact of an expected $988,000 Domestic Manufacturing Deduction which had been limited in prior years by alternative minimum taxes, recognizing $300,000 of research and development credits in the first quarter of 2013 that had been deferred from 2012 pending Congressional action which was completed in January 2013 and the recognition of $53,000 of refundable Ireland research and development credits in the second quarter of 2013, which were received on September 30, 2013.
	The Company regularly assesses the likelihood that the deferred tax assets will be recovered from future taxable earnings.  The Company considers projected future taxable earnings and ongoing tax planning strategies, then records a valuation allowance to reduce the carrying value of the net deferred taxes to an amount that is more likely than not to be realized.
	The Company applies ASC 740, Income Taxes, which clarifies the accounting for uncertainty in tax positions recognized in the financial statements. These provisions create a single model to address uncertainty in tax positions and clarify the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements.  ASC 740 also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition.  The Company has recorded an unrecognized tax benefit of $1,074,000 as of both September 30, 2013 and December 31, 2012.  The impact of tax related interest and penalties is recorded as a component of income tax expense.  As of September 30, 2013, the Company has recorded $-0- for the payment of tax related interest and there were no tax penalties or interest recognized in the statements of operations.
	The Company is subject to income tax examinations in the U.S. Federal jurisdiction, as well as the Republic of Ireland and various state jurisdictions.  Remaining open tax years at September 30, 2013 are 2010 through 2012.

Business_Combinations_and_Asse

Business Combinations and Asset Acquisitions	9 Months Ended
	Sep. 30, 2013
Business Combinations and Asset Acquisitions [Abstract]
Business Combinations and Asset Acquisitions	-12	Business Combinations and Asset Acquisitions
	Shepherd Scientific, Inc.
	On December 21, 2012, the Company acquired the assets relating to the Teirstein Edge™ device organizer and AngioAssist™ docking station from Shepherd Scientific, Inc. (Shepherd Scientific).  Under the terms of the agreement, the Company agreed to pay Shepherd Scientific a total of $500,000, which was paid on December 21, 2012 at closing.  The Teirstein Edge assists in the organization of guidewires and catheters during interventional procedures, while the AngioAssist facilitates the introduction of guidewires into catheters and atherectomy burrs.
	The Company accounted for the transaction as a business combination in the fourth quarter of 2012.   In accordance with ASC 805 the purchase price is being allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Inventory and equipment		$	70,000
	Purchased technology			170,000
	Other intangibles			50,000
	Goodwill			210,000
			$	500,000
	The purchased technology and other intangible assets have an estimated useful life of 9 - 10 years.
	St. Jude Medical, Cardiology Division, Inc.
	On August 16, 2012, the Company acquired the assets related to the Venture® Wire Control Catheter business from St. Jude Medical, Cardiology Division, Inc. (St. Jude Medical).  Under the terms of the agreement, the Company agreed to pay St. Jude Medical a total of $3,000,000, consisting of $2,250,000 paid in cash at August 16, 2012 and $750,000 paid in cash on April 17, 2013, upon the successful completion of the transfer of the manufacturing processes from St. Jude Medical to the Company.  The Venture Wire Control Catheter is used as a deflectable tip catheter for steering a .014 inch guidewire via the arterial system to the coronary or peripheral vasculature.  This acquisition provides the Company with additional products that are sold directly into the Company’s existing customer base to generate incremental revenue.
	The Company accounted for the transaction as a business combination in the third quarter of 2012.   In accordance with ASC 805 the purchase price is being allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Inventory and equipment		$	189,000
	Purchased technology			850,000
	Other intangibles			500,000
	Goodwill			1,461,000
			$	3,000,000
	The purchased technology and other intangible assets have an estimated useful life of 9 - 10 years.  The Company began amortizing the intangible assets when the Company began selling the products in the second quarter of 2013.
	Accumed Systems, Inc.
	On June 11, 2012, the Company acquired the assets related to the AccumedTM wrist positioning splint business from Accumed Systems, Inc. (Accumed).  Under the terms of the agreement, the Company paid Accumed a total of $1,500,000 at closing and no additional payments are required to be made.  The Accumed wrist positioning splint product consists of a plastic molded brace that simplifies arterial access by holding the wrist and forearm in an appropriate, comfortable position.  This acquisition provides the Company with an additional product that is sold directly into the Company’s existing customer base to generate incremental revenue.
	The Company accounted for the transaction as a business combination in the second quarter of 2012.   In accordance with ASC 805 the purchase price is being allocated based on estimates of the fair value of assets acquired, as no liabilities were assumed.
	The purchase price was allocated as follows:
	Inventory and equipment		$	8,000
	Purchased technology			740,000
	Other intangibles			190,000
	Goodwill			562,000
			$	1,500,000
	The purchased technology and other intangible assets have an estimated useful life of 9 - 10 years.
	Dr. Pedro Silva and Affiliates
	On January 6, 2012, the Company entered into an agreement with Dr. Pedro Silva and his affiliates, whereby the Company paid $3,250,000 for the rights, patents and intellectual property relating to a two-lumen catheter for distal protection and material extraction used in the Company’s Pronto® extraction catheters.  Upon payment, the existing License Agreement between N.G.C. Medical S.p.A. and the Company has been deemed paid-in-full, and no royalties are owed on any sale of a Pronto catheter after December 31, 2011.
	The Company accounted for the transaction as a non-business license acquisition in the first quarter of 2012.   In accordance with ASC 805, the purchase price was assigned to a license intangible asset equivalent to the cash amount paid on January 6, 2012, and is being amortized over a period of 10 years.  No goodwill was recognized as part of the transaction.
	Unaudited Supplemental Pro Forma Financial Information
	The following unaudited supplemental pro forma information combines the Company’s results with those of Shepherd Scientific, St. Jude Medical and Accumed as if the acquisitions had occurred at the beginning of each of the periods presented.  This unaudited pro forma information is not intended to represent or be indicative of the Company’s consolidated results of operations or financial condition that would have been reported for the periods presented had the acquisition been completed at the beginning of each of the periods presented, and should not be taken as indicative of the Company’s future consolidated results of operations or financial condition:
			Three Months				Nine Months
			Ended September 30,				Ended September 30,
			2013		2012		2013		2012
	Revenue		$	28,009,000	$	24,625,000	$	81,427,000	$	73,739,000
	Net earnings			2,672,000		2,540,000		7,605,000		6,754,000
	Net earnings per share
	Basic		$	0.16	$	0.16	$	0.47	$	0.42
	Diluted		$	0.16	$	0.15	$	0.45	$	0.41
	Certain pro forma adjustments have been made to reflect the impact of the purchase transaction, primarily consisting of amortization of intangible assets with determinable lives and income taxes to reflect the Company’s effective tax rate for the periods presented.

Products_and_Services

Products and Services	9 Months Ended
	Sep. 30, 2013
Products and Services [Abstract]
Products and Services	-13	Products and Services
	Our broad offering of products is divided into three product categories:
		·	Catheter products, principally consisting of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the Pronto extraction catheters used in treating acute myocardial infarction and the GuideLiner® catheter used to access discrete regions of the coronary anatomy, and also including products used in connection with gaining percutaneous access to the vasculature to perform minimally invasive procedures, such as micro-introducer kits;
		·	Hemostat products, principally consisting of blood clotting products, such as the D-Stat® Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets, and the Vasc Band, a compression device to assist hemostasis following a catheterization or other puncture into a blood vessel in a patient’s arm; and
		·	Vein products and services, principally consisting of the Vari-Lase® endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for radiofrequency vein ablation catheters.
	The following tables set forth, for the periods indicated, net revenue by product category along with the percent change from the previous period:
			Three Months Ended September 30,
			2013					2012
			Net		Percent			Net		Percent
			Revenue		Change			Revenue		Change
	Catheter products		$	17,965,000		17	%	$	15,301,000		15	%
	Hemostat products			5,962,000		7	%		5,567,000		(3	%)
	Vein products and services			3,999,000		11	%		3,597,000		46	%
	Total product revenue			27,926,000		14	%		24,465,000		14	%
	License			83,000		(5	%)		87,000		(97	%)
	Total revenue		$	28,009,000		14	%	$	24,552,000		1	%
			Nine Months Ended September 30,
			2013					2012
			Net		Percent			Net		Percent
			Revenue		Change			Revenue		Change
	Catheter products		$	52,031,000		14	%	$	45,621,000		16	%
	Hemostat products			17,768,000		3	%		17,236,000		(2	%)
	Vein products and services			11,398,000		14	%		9,964,000		29	%
	Total product revenue			81,197,000		12	%		72,821,000		13	%
	License			230,000		(12	%)		262,000		(92	%)
	Total revenue		$	81,427,000		11	%	$	73,083,000		8	%

Net_Earnings_per_Share_Tables

Net Earnings per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Net Earnings per Share [Abstract]
Weighted average common shares outstanding	Weighted average common shares outstanding for the three and nine months ended September 30, 2013 and 2012 were as follows:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
		(unaudited)				(unaudited)
	Weighted average shares outstanding – basic		16,451,000		15,885,000		16,299,000		15,960,000
	Weighted average shares outstanding – diluted		17,067,000		16,389,000		16,894,000		16,341,000

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventories [Abstract]
Inventories	Inventories are stated at the lower of cost (weighted average first-in, first-out method) or market.  Appropriate consideration is given to deterioration, obsolescence and other factors in evaluating net realizable value.  Inventories are comprised of the following:
		September 30,		31-Dec-12
		2013
		(unaudited)
	Raw materials	$	6,292,000	$	6,674,000
	Work-in-process		1,137,000		780,000
	Finished goods		6,831,000		6,283,000
		$	14,260,000	$	13,737,000

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Other Intangible Assets [Abstract]
Goodwill and acquired intangible assets	The changes in the carrying amount of goodwill and acquired intangible assets for the nine months ended September 30, 2013 are as follows:
				Acquired
		Goodwill		Intangibles
		(unaudited)
	Balance at December 31, 2012	$	10,387,000	$	12,325,000
	Amortization		–		(1,162,000	)
	Purchased license		–		900,000
	Foreign currency translation adjustments		44,000		26,000
	Balance at September 30, 2013	$	10,431,000	$	12,089,000

Business_Combinations_and_Asse1

Business Combinations and Asset Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2013
Business Acquisition [Line Items]
Consolidated results of operation or financial condition	The following unaudited supplemental pro forma information combines the Company’s results with those of Shepherd Scientific, St. Jude Medical and Accumed as if the acquisitions had occurred at the beginning of each of the periods presented.  This unaudited pro forma information is not intended to represent or be indicative of the Company’s consolidated results of operations or financial condition that would have been reported for the periods presented had the acquisition been completed at the beginning of each of the periods presented, and should not be taken as indicative of the Company’s future consolidated results of operations or financial condition:
		Three Months				Nine Months
		Ended September 30,				Ended September 30,
		2013		2012		2013		2012
	Revenue	$	28,009,000	$	24,625,000	$	81,427,000	$	73,739,000
	Net earnings		2,672,000		2,540,000		7,605,000		6,754,000
	Net earnings per share
	Basic	$	0.16	$	0.16	$	0.47	$	0.42
	Diluted	$	0.16	$	0.15	$	0.45	$	0.41
Shepherd Scientific, Inc. [Member]
Business Acquisition [Line Items]
Purchase Price Allocation	The purchase price was allocated as follows:
	Inventory and equipment	$	70,000
	Purchased technology		170,000
	Other intangibles		50,000
	Goodwill		210,000
		$	500,000
St. Jude Medical, Cardiology Division, Inc. [Member]
Business Acquisition [Line Items]
Purchase Price Allocation	The purchase price was allocated as follows:
	Inventory and equipment	$	189,000
	Purchased technology		850,000
	Other intangibles		500,000
	Goodwill		1,461,000
		$	3,000,000
Accumed Systems, Inc. [Member]
Business Acquisition [Line Items]
Purchase Price Allocation	The purchase price was allocated as follows:
	Inventory and equipment	$	8,000
	Purchased technology		740,000
	Other intangibles		190,000
	Goodwill		562,000
		$	1,500,000

Products_and_Services_Tables

Products and Services (Tables)	9 Months Ended
	Sep. 30, 2013
Products and Services [Abstract]
Revenue by product category	The following tables set forth, for the periods indicated, net revenue by product category along with the percent change from the previous period:
		Three Months Ended September 30,
		2013					2012
		Net		Percent			Net		Percent
		Revenue		Change			Revenue		Change
	Catheter products	$	17,965,000		17	%	$	15,301,000		15	%
	Hemostat products		5,962,000		7	%		5,567,000		(3	%)
	Vein products and services		3,999,000		11	%		3,597,000		46	%
	Total product revenue		27,926,000		14	%		24,465,000		14	%
	License		83,000		(5	%)		87,000		(97	%)
	Total revenue	$	28,009,000		14	%	$	24,552,000		1	%
		Nine Months Ended September 30,
		2013					2012
		Net		Percent			Net		Percent
		Revenue		Change			Revenue		Change
	Catheter products	$	52,031,000		14	%	$	45,621,000		16	%
	Hemostat products		17,768,000		3	%		17,236,000		(2	%)
	Vein products and services		11,398,000		14	%		9,964,000		29	%
	Total product revenue		81,197,000		12	%		72,821,000		13	%
	License		230,000		(12	%)		262,000		(92	%)
	Total revenue	$	81,427,000		11	%	$	73,083,000		8	%

Net_Earnings_per_Share_Details

Net Earnings per Share (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net Earnings per Share [Abstract]
Weighted average shares outstanding - basic (in shares)	16,451,000	15,885,000	16,299,000	15,960,000
Weighted average shares outstanding - diluted (in shares)	17,067,000	16,389,000	16,894,000	16,341,000

Revenue_Recognition_Details

Revenue Recognition (Details)	9 Months Ended
	Sep. 30, 2013
Revenue Recognition [Abstract]
Restocking charge (in hundredths)	20.00%
Excise tax rate on medical device manufacturers (in hundredths)	2.30%

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventories [Abstract]
Raw materials	$6,292,000	$6,674,000
Work-in-process	1,137,000	780,000
Finished goods	6,831,000	6,283,000
Inventory, Total	$14,260,000	$13,737,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill [Abstract]
Beginning balance			$10,387,000
Foreign currency translation adjustments			44,000
Ending balance	10,431,000		10,431,000
Acquired Intangibles [Abstract]
Beginning balance			12,325,000
Amortization	-404,000	-359,000	-1,162,000	-1,032,000
Purchased license			900,000
Foreign currency translation adjustments			26,000
Ending balance	$12,089,000		$12,089,000

Credit_Risk_and_Allowance_for_1

Credit Risk and Allowance for Doubtful Accounts (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Valuation and Qualifying Accounts Disclosure [Line Items]
Reserves for accounts receivable, net	$200,000	$185,000
Restocking charge (in hundredths)	20.00%
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Reserves for accounts receivable, net	150,000	130,000
Allowance for Sales Returns [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Reserves for accounts receivable, net	$50,000	$55,000

Concentrations_of_Credit_and_O1

Concentrations of Credit and Other Risks (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk, percentage (in hundredths)	85.00%	84.00%	85.00%	84.00%
International Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk, percentage (in hundredths)	15.00%	16.00%	15.00%	16.00%

Dependence_on_Key_Suppliers_De

Dependence on Key Suppliers (Details)	9 Months Ended
	Sep. 30, 2013
Kings Pharmaceuticals [Abstract]
Initial agreement period	10 years
Contract extension period	1 year
Period of written notice to supplier	5 years

Commitments_and_Contingencies_

Commitments and Contingencies (Details)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

69 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Jan. 09, 2007

Apr. 01, 2008

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Jun. 09, 2011

Oct. 20, 2010

31-May-13

Sep. 30, 2013

Dec. 31, 2012

Mar. 31, 2012

Sep. 30, 2011

USD ($)

USD ($)

USD ($)

USD ($)

Terumo Medical Corporation [Member]

Governmental Proceedings [Member]

Governmental Proceedings [Member]

King Agreements [Member]

King Agreements [Member]

King Agreements [Member]

King Agreements [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

Nicolai GmbH Agreement [Member]

Radius Medical Technologies, Inc. [Member]

Radius Medical Technologies, Inc. [Member]

Radius Medical Technologies, Inc. [Member]

Radius Medical Technologies, Inc. [Member]

Radius Medical Technologies, Inc. [Member]

Radius Medical Technologies, Inc. [Member]

Radius Medical Technologies, Inc. [Member]

USD ($)

Vari-Lase [Member]

Vari-Lase [Member]

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Terumo Medical Corporation Litigation [Abstract]

Settlement amount

$812,000

$0

$812,000

$0

$812,000

Governmental Proceedings [Abstract]

Total U.S. sales, maximum

27,926,000

24,465,000

81,197,000

72,821,000

471,000

Total U.S. sales, percentage (in hundredths)

0.10%

Alleged amount of damages

20,000,000

Amortization period for license fee

10 years

Amortization of license fee

153,000

153,000

36,000

73,000

Future amortization of deferred revenue

51,000

Unamortized license fee

662,000

815,000

500,000

0

0

36,000

Nicolai GmbH Agreement [Abstract]

Distribution agreement term

5 years

Radius Medical Technologies, Inc. Contingent Consideration [Abstract]

Business acquisition, cost of acquired entity, purchase price, total

6,449,000

Business acquisition, cost of acquired entity, cash paid

500,000

7,000,000

1,449,000

5,000,000

Percentage of the net sales company is entitled to receive (in hundredths)

25.00%

Annual sales base to compute contingent consideration potential cash payment year one

2,000,000

Annual sales base to compute contingent consideration potential cash payment year two

2,500,000

Annual sales base to compute contingent consideration potential cash payment year three

3,000,000

Range of possible contingent consideration payments value, low

0

Change in fair value of contingent consideration

-79,000

-96,000

-79,000

-136,000

-96,000

-586,000

Business acquisition, contingent consideration recorded

$79,000

Lines_of_Credit_Details

Lines of Credit (Details) (Lines of Credit [Member], USD $)	9 Months Ended
	Sep. 30, 2013
	Covenant
Lines of Credit [Member]
Short-term Debt [Line Items]
Credit agreement period	1 year
Maximum credit limit	$10,000,000
Debt instrument, description of variable rate basis	one-month LIBOR rate plus 1.60%
Debt instrument, basis spread on variable rate (in hundredths)	1.60%
Quarterly loan repayment (in hundredths)	0.13%
Line of credit facility, number of covenants	1
Numerator cash flow leverage ratio, maximum	2.5
Denominator cash flow leverage ratio, maximum	1
Multiple of annual lease expense for covenant calculation	6
Rolling period for computation of covenant	12 months
Line of credit facility, amount outstanding	0
Maximum borrowing capacity	$10,000,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Taxes [Abstract]
Income tax expense (benefit)	$1,352,000	$1,591,000	$3,750,000	$4,338,000
Earnings before income tax	4,024,000	4,156,000	11,355,000	11,196,000
Effective income tax rate (in hundredths)			33.00%	39.00%
Domestic Manufacturing Deduction			988,000
Unrecognized income tax benefits	1,074,000		1,074,000
Tax related interest expense			0
Tax related penalties expense			0
Tax Credit Carryforward [Line Items]
Research and development , tax credit	300,000		300,000
Ireland Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Research and development , tax credit	$53,000		$53,000

Business_Combinations_and_Asse2

Business Combinations and Asset Acquisitions (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		0 Months Ended		12 Months Ended			0 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 21, 2012	Apr. 17, 2013	Aug. 16, 2012	Dec. 31, 2012	Dec. 31, 2012	Jun. 11, 2012	Jan. 06, 2012	Dec. 31, 2012
					Shepherd Scientific, Inc. [Member]	Shepherd Scientific, Inc. [Member]	St. Jude Medical, Cardiology Division, Inc. [Member]	St. Jude Medical, Cardiology Division, Inc. [Member]	St. Jude Medical, Cardiology Division, Inc. [Member]	Accumed Systems, Inc. [Member]	Accumed Systems, Inc. [Member]	Dr. Pedro Silva and Affiliates [Member]	Dr. Pedro Silva and Affiliates [Member]
Purchase price allocation [Abstract]
Business acquisition, cost of acquired entity, purchase price, total						$500,000		$3,000,000			$1,500,000
Business acquisition, cost of acquired entity, cash paid			500,000	7,000,000			750,000	2,250,000
Business acquisition, purchase price allocation, liabilities assumed						0		0			0
Acquired indefinite-lived intangible asset, amount												3,250,000
Purchase price asset allocation [Abstract]
Inventory and equipment						70,000		189,000			8,000
Purchased technology						170,000		850,000			740,000
Other intangibles						50,000		500,000			190,000
Goodwill						210,000		1,461,000			562,000
Total asset purchase price allocation						500,000		3,000,000			1,500,000
Estimated useful life of purchased technology and other intangible assets, minimum					9 years				9 years	9 years
Estimated useful life of purchased technology and other intangible assets, maximum					10 years				10 years	10 years
Estimated useful life of purchased technology and other intangible assets													10 years
Business acquisition, pro forma information [Abstract]
Revenue	28,009,000	24,625,000	81,427,000	73,739,000
Net earnings	$2,672,000	$2,540,000	$7,605,000	$6,754,000
Net earnings per share [Abstract]
Basic (in dollar per share)	$0.16	$0.16	$0.47	$0.42
Diluted (in dollar per share)	$0.16	$0.15	$0.45	$0.41

Products_and_Services_Details

Products and Services (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Product Information [Line Items]
Total revenue	$28,009,000	$24,552,000	$81,427,000	$73,083,000
Total revenue percentage change (in hundredths)	14.00%	1.00%	11.00%	8.00%
Catheter Products [Member]
Product Information [Line Items]
Total revenue	17,965,000	15,301,000	52,031,000	45,621,000
Total revenue percentage change (in hundredths)	17.00%	15.00%	14.00%	16.00%
Hemostat Products [Member]
Product Information [Line Items]
Total revenue	5,962,000	5,567,000	17,768,000	17,236,000
Total revenue percentage change (in hundredths)	7.00%	-3.00%	3.00%	-2.00%
Vein Products and Services [Member]
Product Information [Line Items]
Total revenue	3,999,000	3,597,000	11,398,000	9,964,000
Total revenue percentage change (in hundredths)	11.00%	46.00%	14.00%	29.00%
Total Product Revenue [Member]
Product Information [Line Items]
Total revenue	27,926,000	24,465,000	81,197,000	72,821,000
Total revenue percentage change (in hundredths)	14.00%	14.00%	12.00%	13.00%
License [Member]
Product Information [Line Items]
Total revenue	$83,000	$87,000	$230,000	$262,000
Total revenue percentage change (in hundredths)	-5.00%	-97.00%	-12.00%	-92.00%